Celgene's CAR-T and Glaxosmithkline's antibody-drug conjugate are among the industry's most valuable R&D assets.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Analysis of me-too drug approvals over time shows trends across therapy areas.
Bristol-Myers Squibb has come out on top of an analysis of efficiency in big pharma. Being in immuno-oncology might have helped – but so might aggressive job cuts.
The drugs of 2014 that went supernova and those that failed to make orbit.
Gilead and Abbvie feel the heat as forecasts shrink for their top drugs, while Biogen's Spinraza exceeds expectations.
The price of early stage cancer assets leaves Celgene shelling out $3.5bn in upfront payments, with no end in sight for rising valuations.
As companies retreat from M&A licensing deal valuations hit new peak.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?